FAIRFAX, Va.--(BUSINESS WIRE)--Marine Corps Base Quantico – National Capital Region (RCO-NCR) has awarded the GenTech Partners joint venture team of ManTech International Corporation (NASDAQ: MANT) and Genex Systems, LLC, a prime contract to provide the Marine Corps Warfighting Laboratory (MCWL) with a full range of engineering, analytical, technical, and business services. The contract and all option years are valued at $23 million.
“The Marine Corps Warfighting Laboratory plays an important role in the technological advancement of Marine Corps capabilities”
The MCWL was established in 1995 with the mandate to develop the future vision and map the future capabilities for the Marine Corps as an integral part of the combat development process. The MCWL works closely with the Office of Naval Research and the Defense Advanced Research Projects Agency.
“The Marine Corps Warfighting Laboratory plays an important role in the technological advancement of Marine Corps capabilities," said Louis M. Addeo, president and chief operating officer of ManTech’s Technical Services Group. “We have established a strong working relationship with our joint venture partner, Genex, and we look forward to contributing to the continued effectiveness of the Marine Corps warfighter.”
About ManTech International Corporation
ManTech is a leading provider of innovative technologies and solutions for mission-critical national security programs for the intelligence community; the Department of Defense, including its health organizations; the departments of State, Homeland Security, Energy and Justice, including the Federal Bureau of Investigation (FBI); the space community; and other U.S. federal government customers. We provide support to critical national security programs for approximately 60 federal agencies through approximately 1,000 current contracts. ManTech's expertise includes command, control, communications, computers, intelligence, surveillance and reconnaissance (C4ISR) lifecycle support; cyber security; global logistics support; intelligence/counter-intelligence support; information technology (IT) modernization and sustainment; systems engineering; test and evaluation; and health IT. ManTech supports major national missions, such as military readiness, terrorist threat detection, information security and border protection. Additional information on ManTech can be found at www.mantech.com.
Statements and assumptions made in this press release, which do not address historical facts, constitute "forward-looking" statements that ManTech believes to be within the definition in the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties, many of which are outside of our control. These forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes we anticipate. Factors that could cause actual results to differ materially from those we anticipate include, but are not limited to: adverse changes in U.S. government spending levels for programs we support due to budgetary constraints affecting federal government spending, changing mission priorities or other factors; failure to obtain option awards, task orders or funding under the contract; risk of contract renegotiation, performance, modification or termination; competition; failure to maintain strong relationships with other contractors; and risks associated with complex U.S. government procurement laws. These and other risk factors are more fully discussed in the section entitled "Risks Factors" in ManTech's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on Feb. 24, 2012, and from time to time in ManTech's other filings. The forward-looking statements included in this news release are only made as of the date of this press release, and ManTech undertakes no obligation to publicly update any of the forward-looking statements made herein, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.